Small molecule Rx therapeutics: the foundations for innovation
How early strategic decisions in formulation, drug delivery system and infrastructure shape the success of small molecule Rx programs — the Formulated Solutions approach.
Executive summary
Small molecule prescription (Rx) therapeutics remain the backbone of modern medicine, addressing a wide range of chronic and complex conditions where efficacy, safety and patient adherence are critical. In this eBook, we explore how early strategic decisions shape the success of Rx programs.
Readers will learn how to navigate common formulation hurdles, such as solubility and bioavailability challenges, and gain insights into how patient-centric drug delivery systems can improve usability and adherence. We examine how phase-appropriate planning and adaptable infrastructure can reduce risks, accelerate development and set the stage for long-term success — an approach central to how Formulated Solutions supports partners across the small molecule Rx journey.
Preparing for the next Rx-traordinary breakthrough
The landscape of pharmaceutical development is vast and varied, encompassing everything from over-the-counter (OTC) medications to biologics, controlled substances and highly regulated small molecule prescription (Rx) drugs. While OTC products are readily available for self-treatable symptoms and supplements cater to general wellness, prescription drugs are specifically designed for severe or chronic conditions that require a prescription under the supervision of a licensed medical doctor. This fundamental difference means the development of Rx drugs operates under a significantly higher level of regulation, overseen by bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), as well as numerous other governmental oversight bodies around the globe.
The core objective of a small molecule Rx drug product is to deliver a therapeutic to a specific target within the human body, focusing on balancing efficacy, toxicity and the bioavailability of the active ingredient within a clinically efficacious therapeutic window.
As Rx drugs are designed for specific medical indications and are tied to the specific dosage format being studied via human clinical trials, label claims are paramount and need to be supported by clinical data. Early-stage decisions regarding formulation design and drug delivery systems are critical. Choosing between a semi-solid or a liquid formulation, and dosage forms such as nasal or topical, can have profound and long-lasting impacts on scalability, cost, patient adherence, patient-to-patient variability and, ultimately, clinical success.
Without the right foundational strategy, drug developers can expect to face significant hurdles or even outright failure later in the small molecule Rx drug development process. If the final delivery system is not considered early enough, it may lead to delays, additional costs or even a less effective product. Overcoming this at a later stage will require additional development with supporting clinical and stability data, which could take years to complete, potentially jeopardizing the entire project.
This makes early support from a capable contract development and manufacturing organization (CDMO) more valuable than ever. Proactive planning, flexible thinking and an experienced partnership are essential for reducing downstream risks and positioning small molecule Rx programs for long-term success. Understanding the nuances of regulatory pathways, from toxicology studies to Phase 1, 2 and 3 clinical trials and into commercialization, is a significant complexity, and often follows a non-linear path. A CDMO that can offer comprehensive support "under one roof" can significantly streamline this intricate process.
Strategy for success: building the right foundations
Successful drug development is a complex journey, where early strategic decisions lay the groundwork for long-term success. At Formulated Solutions, we understand that building the right foundations from the outset — across formulation, drug delivery system and infrastructure — is paramount to navigating challenges and accelerating your path to market.
Formulation
How to get it right, right from the start.
Delivery system
Think beyond the molecule.
Infrastructure
Plan for where you're going, not just where you are.
Formulation: how to get it right, right from the start
The heart of any small molecule Rx therapeutic lies in the combination of a clinically efficacious active pharmaceutical ingredient (API), combined with a formulation and drug delivery system that optimizes product performance with patient adherence. The new wave of APIs often presents significant formulation challenges, with approximately 80% requiring specialized expertise to ensure efficacy, bioavailability and stability. Of drugs currently under development, an estimated 70–90% are poorly water-soluble, falling into developability classification system (DCS) Classes II (low solubility, high permeability) and IV (low solubility, low permeability).
Addressing these complexities as early as possible in the drug development cycle is crucial, typically balanced with phase-appropriate development strategies that require risk-based planning prior to registration batches and commercial launch.
Early formulation work — rapid screening, phase-appropriate analytical methods and small-scale prototyping — is crucial in building the knowledge base to understand how best to address critical drug product issues such as bioavailability, solubility, manufacturability and drug product stability. Agile approaches enable formulation experts to quickly test and refine strategies, striking a balance between speed and scientific rigor, adapting to evolving data. This is even further accelerated today by advances in artificial intelligence and the ability to rapidly screen large data sets that would have previously been resource constrained.
Apply the right formula and success is inevitable
Our development teams bring deep expertise in solving complex formulation challenges across topicals, nasal sprays, aerosols and non-sterile liquids. Key capabilities include small-scale prototyping to test molecules efficiently, enhancing API bioavailability profiles, deep experience with DCS Class II & IV molecules, and integrated formulation and packaging development that ensures the delivery method supports both therapeutic performance and patient usability. Our agile approach enables fast, informed decisions, so your formulation keeps pace with your program.
Delivery system: think beyond the molecule
Selecting the optimal drug delivery system early in development can be a daunting task, especially when formats like aerosols initially appear cost-prohibitive. However, thinking beyond the molecule itself to consider the broader patient experience, as well as the manufacturability and scalability of different delivery systems, helps accomplish this goal.
Exploring multiple delivery systems in parallel — for example, simultaneous prototyping and stability testing of a liquid formulation alongside an aerosol, topical or nasal version — offers strategic advantages. This approach provides a deeper understanding of your formulation and ensures delivery system decisions are aligned with future commercial goals, minimizing risk. Although it may initially require more testing upfront, exploring different delivery systems in parallel can reduce overall project costs and lead to long-term cost efficiencies by avoiding costly rework later in the development cycle.
In a Cochrane review, Haynes et al. noted that increasing the effectiveness of adherence interventions may have a far greater impact on population health than any improvement in specific medical treatments. The World Health Organization has similarly declared medication adherence a global health issue. It is widely cited that nearly half of all prescribed medications are not taken as intended, with a range of physical, logistical and psychological barriers preventing patients from fully benefiting from their therapies.
Patient-centric design in practice
- Foam vehicles that are highly effective for topical medications on hair-bearing skin — engineered to collapse into a light, non-greasy liquid or film upon contact with the skin, minimizing discomfort and mechanical abrasion on sensitive or inflamed skin.
- Engineered delivery formats for hospital use, such as unit-dose packaging and minimal-touch application systems, which mitigate cross-contamination risks while simplifying the process for healthcare professionals.
- Topical medications that are light, breathable and cosmetically elegant, more readily integrated into patients' daily routines due to their pleasant sensory appeal and convenience.
Why patient-centric delivery matters
Innovations like our eN2fused™ foam technology exemplify Formulated Solutions' commitment to patient-centric design. This proprietary, patented innovation enables the creation of whipped versions of even thick creams and ointments, making them significantly more spreadable. This is crucial for applying products to irritated or wounded skin, where traditional high-viscosity applications can cause pain or further damage — reducing mechanical abrasion, enhancing patient comfort and helping promote adherence.
Infrastructure: plan for where you're going, not just where you are
Successfully advancing a small molecule Rx drug from early-stage development to commercial launch depends on numerous factors coming together — most important of which is successful clinical trial data, but also having the right infrastructure in place, both in terms of physical capacity and operational flexibility. As a product moves through development stages — IND-enabling early formulations, early-stage clinical trials, further formulation optimization, scale-up, readiness for late-stage clinical trials, marketing authorization approval and commercialization — its manufacturing, regulatory and logistical requirements shift.
Few CDMO partners offer end-to-end capabilities, including primary and secondary packaging for commercial distribution. Many are equipped for either early-stage work or commercial manufacturing, but not both, forcing sponsors to transfer their program between multiple CDMOs — introducing complexity, cost and potential quality variability. A more integrated infrastructure, one that supports both small-scale clinical supply and large-scale production, allows the development team to retain and build on their product-specific expertise and helps maintain continuity throughout a program's lifecycle.
Quality oversight and regulatory compliance is another critical consideration. A unified quality management system that spans all development and manufacturing activities helps ensure consistency and compliance with regulatory expectations. U.S.-based manufacturing sites may offer strategic advantages including streamlined logistics, reduced geopolitical exposure, and easier site access, with flexible GMP space that can be tailored to accommodate specific formats, batch sizes or processing equipment.
Built to scale with you
Formulated Solutions offers end-to-end Rx drug development and manufacturing capabilities, all under one roof. Our GMP manufacturing sites, based in Largo, Florida, and Cleveland, Tennessee, provide flexible GMP space with custom build-out opportunities, scalable operations from early-stage innovation to large-scale commercial production, and U.S.-based manufacturing for greater supply chain stability. We operate under a strong, unified GMP quality system spanning both facilities, with a regulatory history that includes numerous customer and regulatory agency audits demonstrating our adherence to FDA requirements and ISO certifications.
Inside the Partner Innovation Suite
The Partner Innovation Suite is a testament to Formulated Solutions' commitment to collaborative development and innovation. A dedicated on-site space in Largo, Florida, it allows client teams to work directly alongside our chemists, facilitating seamless knowledge transfer and ensuring your drug product is nurtured with the utmost care and involvement. It provides a secure and inviting environment for client teams to co-develop, execute Design of Experiments (DOEs) and facilitate tech transfer alongside our experts — equipped with analytical tools and direct access to our full suite of resources for deep engagement and real-time learning.
Heading for the horizon in Rx development and manufacturing
As we look toward the future of small molecule Rx therapeutics, including semi-solids or liquids and various applications such as topical or nasal, it becomes increasingly clear that successful drug development is not solely a triumph of scientific discovery. While groundbreaking science is undeniably the foundation, the journey from concept to commercialization is shaped by strategic decisions made early in the process — specifically concerning formulation, delivery system and the underlying infrastructure. These foundational choices dictate the trajectory, efficiency and ultimate success of an Rx program, as well as future life cycle management decisions for prescription drug products.
The value of partnering with an experienced CDMO that offers integrated support, cross-functional insight and flexible infrastructure cannot be overstated. Formulated Solutions brings a holistic approach to every stage of development, ensuring that early decisions are made with a clear line of sight to commercial viability and patient adherence, spanning the entire lifecycle from initial formulation development and small-scale prototyping to large-scale commercial manufacturing.
Have you tried the Formulated Solutions approach to Rx?
In pharmaceutical development, innovation is constant, but success depends on more than scientific breakthroughs alone. It demands a strategic partner capable of navigating the complexities of formulation, drug delivery systems and manufacturing infrastructure. Formulated Solutions is that partner — a CDMO purpose-built for small molecule Rx innovators, offering end-to-end support from initial concept and formulation through full-scale commercial manufacturing.
Deep expertise in complex formats
Unparalleled knowledge developing and manufacturing topicals, aerosols, nasals and small molecule liquid formulations, informed by cross-functional experience spanning Rx, OTC and clinical trials.
Parallel-path delivery system development
We prototype and test multiple drug delivery systems in parallel — even those initially perceived as costly — to identify the most effective, patient-preferred format.
Proprietary technologies
Innovations like our patented eN2fused™ foam exemplify our commitment to design-led, compliance-boosting drug delivery systems.
Flexible, GMP-compliant infrastructure
State-of-the-art U.S.-based GMP facilities designed to scale with you, from clinical supply to commercial launch, under a unified, robust quality system — underscored by our Partner Innovation Suite's hands-on, collaborative development model.
The journey of an Rx therapeutic has many critical decision points. The strategic guidance, flexibility and technical insight provided by Formulated Solutions can make the most significant difference, especially when engaged early in your journey. We invite you to connect with us to explore how our integrated approach can de-risk your program, optimize your product and position you for a truly Rx-traordinary breakthrough.
Download the full PDF: Small Molecule Rx Therapeutics eBook (PDF)
References
1. Konagurthu, S. (2025, April 1). Combining the power of human and technological innovation to combat drug formulation challenges. American Pharmaceutical Review. americanpharmaceuticalreview.com
2. Benet LZ. The Role of BCS and BDDCS in Drug Development. Journal of Pharmaceutical Sciences. 2013;102(1):34–42.
3. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;(2):CD000011.
4. World Health Organization. (2003). Adherence to long-term therapies: Evidence for action. iris.who.int/handle/10665/42682
5. Chapman, S. C. E., & Chan, A. H. Y. (2025). Medication nonadherence — definition, measurement, prevalence, and causes. Frontiers in Pharmacology, 16, Article 1465059. doi.org/10.3389/fphar.2025.1465059
